Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
May 31 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that Jay R. Luly, Ph.D.,
President and Chief Executive Officer, will participate in a
fireside chat at Jefferies Global Healthcare Conference on June 7,
2023 at 12:30 p.m. ET in New York, NY.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcast will be
available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research on a single agent
targeting both RSV and human metapneumovirus (hMPV).
Enanta receives royalties from hepatitis C virus (HCV) products
developed under its collaboration with AbbVie. Glecaprevir, a
protease inhibitor discovered by Enanta, is part of one of the
leading treatment regimens for curing chronic HCV infection and is
sold by AbbVie in numerous countries under the tradenames MAVYRET®
(U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please
visit www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005208/en/
Media and Investors Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024